Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

  • Reacquired exclusive, global rights to develop and commercialize Amylin's exenatide franchise and began discussions with potential partners to develop and commercialize exenatide outside the U.S.
  • Initiated expansion of the Amylin sales force to 715 diabetes sales specialists completely focused on Amylin products with more efficient targeting.
  • Received FDA approval for a new use for BYETTA® (exenatide) injection, making it the only short-acting GLP-1 agonist approved for use as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione (TZD).
  • Submitted an Investigational New Drug application for AC165198, a new fusion peptide developed under Amylin's collaboration with Biocon, Limited. The first clinical study for this potential therapy for diabetes was initiated in January 2012.

  • Quarter Ended December 31, 2011Net product sales of $160.9 million for the quarter ended December 31, 2011 include $132.6 million for BYETTA and $28.3 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $162.3 million, consisting of $136.4 million for BYETTA and $25.9 million for SYMLIN for the same period in 2010. Revenues under collaborative agreements were $4.1 million for the quarter ended December 31, 2011, compared to $11.9 million for the same period in 2010, which included $10 million in milestone revenue earned upon the launch of BYETTA in Japan.

    Selling, general and administrative expenses increased to $78.3 million for the quarter ended December 31, 2011 from $62.5 million for the same period in 2010. The increase primarily reflects expenses associated with BYDUREON pre-launch activities.  

    Research and development expenses decreased to $27.7 million for the quarter ended December 31, 2011 from $37.5 million for the same period in 2010. The decrease reflects the favorable disposition of certain cost-sharing disputes with Eli Lilly and Com
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
    5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
    8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
    10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... GRAND RAPIDS, Mich. , Jan. 15, 2014 As ... of the flu virus, select Meijer pharmacies in ... and strep throat to eligible patients, enabling Meijer pharmacists to ... under strict protocol set by a physician participating in the ...
    (Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
    (Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
    Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
    ... Speakers Group (WWSG) , an innovative leader transforming the ... is proud to announce its exclusive representation of ... Human Services Secretary, EPA Administrator and three-term governor of ... in both the private and public sectors, Governor Leavitt ...
    ... 19 Accium BioSciences, a leading provider of bioanalytical ... today new pricing for its AMS measurement service at ... $115 per sample. The new pricing includes sample graphitization ... expert bioanalytical and quality assurance services at competitive rates. ...
    Cached Medicine Technology:Governor Michael O. Leavitt, Former HHS Secretary and EPA Administrator, Selects WorldWide Speakers Group for Exclusive Representation 2Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service 2
    (Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
    (Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
    (Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
    (Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
    (Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
    Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
    ... risk of type 2 diabetesPORT ST. LUCIE, Fla., March 24 ... Diabetes Association urges all Americans to learn about type 2 ... educate the public, the American Diabetes Association and one of ... up to provide an online video that explains the symptoms ...
    ... Offers New Option for Adult Patients Suffering From ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: ... Food and Drug Administration (FDA) approved TYGACIL(R) (tigecycline), ... bacterial pneumonia (CABP) caused by susceptible strains of ...
    ... drives Victoria,s Secret Fashion Show and Armani Exchange model ... a cureHOLLYWOOD, Fla., March 24 Brazilian supermodel Izabel ... Ambassador for the Diabetes Research Institute Foundation, the nonprofit ... at the world-renowned Diabetes Research Institute (DRI) at the ...
    ... Israel, Iran, Saudi Arabia, Kuwait, the United Arab Emirates ... in Indianapolis April 1 and 2 for the First ... , A unique event, this conference will bring together ... foster collaboration between physicians from Western and Middle Eastern ...
    ... laser surgeon in Beverly Hills, appeared on The Doctors TV Show, ... the most comprehensive center specializing in laser technology and non-invasive aesthetic ... ... Beverly Hills, CA (PRWEB) March 24, 2009 -- Dr. Simon ...
    ... California is making health care easier and more accessible ... Proveedor Medico , the Spanish version of its existing English ... allows all visitors - even if they,re not yet Blue ... doctors and hospitals to help them make more informed decisions ...
    Cached Medicine News:Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 2Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 4Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 2Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 3Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 4Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 5Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 6Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 7Health News:Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador 2Health News:Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador 3Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 2Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 3Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 4Health News:Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider 2Health News:Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider 3
    ... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
    ... The new Synchron LXi 725 clinical ... with highly accurate immunoassay testing capabilities, ... handling on a single platform. After ... automatically repeated for optimal quality assurance. ...
    ...
    ...
    Medicine Products: